4. The use of claim 2, wherein the compound of formula Ia or the salt thereof is to be administered sequentially with the vemurafenib or a pharmaceutically acceptable salt thereof.

5. The use of claim 2, wherein the compound of formula Ia or the salt thereof and the vemurafenib or a pharmaceutically acceptable salt thereof is to be administered separately.

6. The use of any one of claims 2-5 wherein the cancer comprises a BRAF V600E mutation.

7. The use of any one of claims 2-5 wherein the cancer is associated with high pAKT expression or activation levels.

8. The use of any one of claims 2-7 wherein the cancer is lymphoma, colon, melanoma, thyroid or lung cancer.

9. The use of claim 8 wherein the cancer is resistant to vemurafenib single agent therapy.

10. The use of claim 9 wherein the cancer is metastatic or unresectable melanoma.

11. The use of any one of claims 1-10 wherein the combination provides a synergistic effect in treating the disorder.

12. A compound of formula Ia



Ia

or a pharmaceutically acceptable salt thereof, for therapeutic use for improving the quality of life of a patient treated for cancer with vemurafenib or a pharmaceutically acceptable salt thereof.

13. Use of a) a compound of formula Ia



Ia

or a pharmaceutically acceptable salt thereof; and b) vemurafenib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a mammal, wherein the cancer is modulated by BRAF V600E mutation.

14. The use of claim 13, wherein the mammal is a patient, wherein said patient previously received vemurafenib single agent therapy.

15. A kit comprising ~~a compound of formula Ia~~



~~Ia~~

~~or a pharmaceutically acceptable salt thereof~~the combination as defined in claim 1, a container, and a package insert or label indicating the administration of the ~~compound of formula Ia with vemurafenib or a pharmaceutically acceptable salt thereof for treating cancer~~ combination as defined in claim 1, for use in the therapeutic treatment of a hyperproliferative disease.